Clinical Trial Update: EPO906 in Carcinoid and Other Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of EPO906 (irofulven) in carcinoid tumors and other neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor

Drugs mentioned

• EPO906

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoid, Neuroendocrine Tumors | Phase 2 | Status: COMPLETED